Literature DB >> 25896088

Multiple sclerosis: Switching sides--fingolimod versus injectable MS therapies.

Ian T Rossman1, Jeffrey A Cohen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25896088     DOI： 10.1038/nrneurol.2015.59

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.

Authors:  Anna He; Tim Spelman; Vilija Jokubaitis; Eva Havrdova; Dana Horakova; Maria Trojano; Alessandra Lugaresi; Guillermo Izquierdo; Pierre Grammond; Pierre Duquette; Marc Girard; Eugenio Pucci; Gerardo Iuliano; Raed Alroughani; Celia Oreja-Guevara; Ricardo Fernandez-Bolaños; Francois Grand'Maison; Patrizia Sola; Daniele Spitaleri; Franco Granella; Murat Terzi; Jeannette Lechner-Scott; Vincent Van Pesch; Raymond Hupperts; José Luis Sánchez-Menoyo; Suzanne Hodgkinson; Csilla Rozsa; Freek Verheul; Helmut Butzkueven; Tomas Kalincik
Journal:  JAMA Neurol       Date:  2015-04       Impact factor: 18.302

Review 2.  A tutorial on methods to estimating clinically and policy-meaningful measures of treatment effects in prospective observational studies: a review.

Authors:  Peter C Austin; Andreas Laupacis
Journal:  Int J Biostat       Date:  2011-01-06       Impact factor: 0.968

Review 3.  Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials.

Authors:  Andrew Anglemyer; Hacsi T Horvath; Lisa Bero
Journal:  Cochrane Database Syst Rev       Date:  2014-04-29

4.  Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

Authors:  Bhupendra Khatri; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Ludwig Kappos; Xavier Montalban; Jean Pelletier; Tracy Stites; Stacy Wu; Fred Holdbrook; Lixin Zhang-Auberson; Gordon Francis; Jeffrey A Cohen
Journal:  Lancet Neurol       Date:  2011-05-13       Impact factor: 44.182

5.  Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.

Authors:  Dalia L Rotstein; Brian C Healy; Muhammad T Malik; Tanuja Chitnis; Howard L Weiner
Journal:  JAMA Neurol       Date:  2015-02       Impact factor: 18.302

6.  MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis.

Authors:  H Butzkueven; J Chapman; E Cristiano; F Grand'Maison; M Hoffmann; G Izquierdo; D Jolley; L Kappos; T Leist; D Pöhlau; V Rivera; M Trojano; F Verheul; J P Malkowski
Journal:  Mult Scler       Date:  2006-12       Impact factor: 6.312

7.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Authors:  Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Bhupendra O Khatri; Xavier Montalban; Jean Pelletier; Ruggero Capra; Paolo Gallo; Guillermo Izquierdo; Klaus Tiel-Wilck; Ana de Vera; James Jin; Tracy Stites; Stacy Wu; Shreeram Aradhye; Ludwig Kappos
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

8.  Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.

Authors:  Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Guillermo Izquierdo; Bhupendra Khatri; Xavier Montalban; Jean Pelletier; Benjamin Eckert; Dieter A Häring; Gordon Francis
Journal:  J Neurol       Date:  2013-04-30       Impact factor: 4.849

9.  Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study.

Authors:  Niklas Bergvall; Charles Makin; Raquel Lahoz; Neetu Agashivala; Ashish Pradhan; Gorana Capkun; Allison A Petrilla; Swapna U Karkare; Catherine Balderston McGuiness; Jonathan R Korn
Journal:  PLoS One       Date:  2014-02-06       Impact factor: 3.240

10.  Defining the clinical course of multiple sclerosis: the 2013 revisions.

Authors:  Fred D Lublin; Stephen C Reingold; Jeffrey A Cohen; Gary R Cutter; Per Soelberg Sørensen; Alan J Thompson; Jerry S Wolinsky; Laura J Balcer; Brenda Banwell; Frederik Barkhof; Bruce Bebo; Peter A Calabresi; Michel Clanet; Giancarlo Comi; Robert J Fox; Mark S Freedman; Andrew D Goodman; Matilde Inglese; Ludwig Kappos; Bernd C Kieseier; John A Lincoln; Catherine Lubetzki; Aaron E Miller; Xavier Montalban; Paul W O'Connor; John Petkau; Carlo Pozzilli; Richard A Rudick; Maria Pia Sormani; Olaf Stüve; Emmanuelle Waubant; Chris H Polman
Journal:  Neurology       Date:  2014-05-28       Impact factor: 9.910
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.